{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:29:24Z","timestamp":1774056564285,"version":"3.50.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder characterized by complement-mediated hemolysis, thrombosis, and bone marrow failure. Iptacopan, an oral factor B inhibitor, has demonstrated efficacy in managing PNH but has not been studied in patients with severe renal insufficiency. We report a case of a PNH patient with end-stage renal disease who required renal replacement therapy and had a peritoneal dialysis catheter placed during treatment. After switching from eculizumab to iptacopan, the patient achieved transfusion independence, sustained hematologic improvement, and resolution of both intravascular and extravascular hemolysis. Iptacopan was well tolerated, with only mild adverse effects and no breakthrough hemolysis or infections. This case highlights the potential of iptacopan as a therapeutic option in PNH patients with severe renal impairment requiring dialysis.<\/jats:p>","DOI":"10.3389\/fmed.2025.1583394","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:24:25Z","timestamp":1754371465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Iptacopan in a paroxysmal nocturnal hemoglobinuria patient with severe renal insufficiency"],"prefix":"10.3389","volume":"12","author":[{"given":"Ting","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1182\/blood-2010-08-304071","article-title":"A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA working Party of the European Group for blood and marrow transplantation","volume":"117","author":"Tichelli","year":"2011","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s00277-019-03735-6","article-title":"Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis","volume":"98","author":"Kim","year":"2019","journal-title":"Ann Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1177\/10815589241254046","article-title":"Advances in research on renal injury in paroxysmal nocturnal hemoglobinuria","volume":"72","author":"Li","year":"2024","journal-title":"J Investig Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1056\/NEJMc1010351","article-title":"Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab","volume":"363","author":"Risitano","year":"2010","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/ejh.13970","article-title":"Long-term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real-world setting","volume":"111","author":"Versmold","year":"2023","journal-title":"Eur J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial","volume":"8","author":"Risitano","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1182\/bloodadvances.2022006960","article-title":"Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study","volume":"6","author":"Jang","year":"2022","journal-title":"Blood Adv"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral Iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e67830","DOI":"10.7759\/cureus.67830","article-title":"Iptacopan efficacy and safety to treat paroxysmal nocturnal hemoglobinuria (PNH): a systematic review and Meta-analysis","volume":"16","author":"Dighriri","year":"2024","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1124\/dmd.123.001290","article-title":"Absorption, distribution, metabolism, and excretion of [(14)C]iptacopan in healthy male volunteers and in in vivo and in vitro studies","volume":"51","author":"James","year":"2023","journal-title":"Drug Metab Dispos"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1583394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:24:28Z","timestamp":1754371468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1583394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":12,"alternative-id":["10.3389\/fmed.2025.1583394"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1583394","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"article-number":"1583394"}}